1-6 of 6
Ali Rana
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

Lori A. Leslie, Chan Y. Cheah, Franck Morschhauser, Justin M. Darrah, Joshua Brody, David Belada, Juraj Duras, Joost S.P. Vermaat, Gerardo Musuraca, Kojo Osei-Bonsu, Yi Hao, Kimberly G. Archer, Monica Wielgos-Bonvallet, Ali Rana, Yasmin H. Karimi
Journal: Blood
Blood (2024) 144 (Supplement 1): 3106.
https://doi.org/10.1182/blood-2024-199652
Published: 2024
Journal Articles

Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial

Lorenzo Falchi, Fritz Offner, Sven de Vos, Joshua Brody, Raul Cordoba, Kim Linton, Sylvia Snauwaert, Michael Roost Clausen, Toshihiko Oki, Andrew J. Steele, Yi Hao, Kimberly G. Archer, Ali Rana, David Belada
Journal: Blood
Blood (2024) 144 (Supplement 1): 581.
https://doi.org/10.1182/blood-2024-198023
Published: 2024
Journal Articles

Epcoritamab SC + R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: First Disclosure from Arm 8 of the Epcore NHL-2 Trial

Joost S.P Vermaat, Joshua Brody, Juraj Ďuraš, Yasmin H. Karimi, Chan Y. Cheah, Justin M. Darrah, Gerardo Musuraca, Franck Morschhauser, Daniela Hoehn, Ali Rana, Yaou Song, Pegah Jafarinasabian, David Belada
Journal: Blood
Blood (2023) 142 (Supplement 1): 4457.
https://doi.org/10.1182/blood-2023-180935
Published: 2023
Journal Articles

Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results

Pau Abrisqueta, Raul Cordoba, Lorenzo Falchi, Sven de Vos, Marcel Nijland, Fritz Offner, Jun Wu, Irina Bykhovski, Liwei Wang, Ali Rana, Tycel Phillips
Journal: Blood
Blood (2022) 140 (Supplement 1): 1068–1069.
https://doi.org/10.1182/blood-2022-158278
Published: 2022
Journal Articles

Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update

Lorenzo Falchi, Pau Abrisqueta, Marcel Nijland, Sirpa Leppä, Martin Hutchings, Harald Holte, Reid W Merryman, Pieternella Lugtenburg, Sven de Vos, Chan Y. Cheah, Jacob Haaber Christensen, Luca Arcaini, Kristina Drott, Mats Hellström, Lori A. Leslie, Umberto Vitolo, Ali Rana, Aqeel Abbas, Liwei Wang, Minh Dinh, David Belada
Journal: Blood
Blood (2022) 140 (Supplement 1): 1464–1466.
https://doi.org/10.1182/blood-2022-158203
Published: 2022
Journal Articles

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R 2 ) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Lorenzo Falchi, Lori A. Leslie, David Belada, Katerina Kopeckova, Fritz Offner, Joshua Brody, Miguel Canales, Alejandro Martín García-Sancho, Marcel Nijland, P-O Andersson, Farrukh T. Awan, Jacob Haaber Christensen, Kristina Drott, Mats Hellström, Catharina Lewerin, Mayur Narkhede, Sylvia Snauwaert, Björn E Wahlin, Ali Rana, Aqeel Abbas, Liwei Wang, Minh Dinh, Joost S.P. Vermaat, Pau Abrisqueta
Journal: Blood
Blood (2022) 140 (Supplement 1): 1471–1473.
https://doi.org/10.1182/blood-2022-158232
Published: 2022